Stockreport

Nektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemia [Seeking Alpha]

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations
PDF with an autologous bispecific chimeric antigen receptor CAR-T cell therapy led to relapse-free/progression-free survival of 68%, compared to 38% seen in historical contr [Read more]